HCV Kinetics in IFN-treated patients is related to treatment schedule and to viral genotype
Angelo Rossini(Centro Universitário Barão de Mauá), E. Radaeli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), C. Almerighi(Sapienza University of Rome), Marco Artini(Fondazione Andrea Cesalpino), Massimo Levrero(Northwest Medical Specialties), L. Biasi(University of Brescia), Elisabetta Cariani(University of Parma), Marco Massari(Azienda Sanitaria Unità Locale di Reggio Emilia)
Cited by 1
Related Papers
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
|Gut|2015|273
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133